Cone-beam computed tomography (CBCT) has an important function in understanding implant operations. CBCT can be used to evaluate the basic condition of implant site before implant operation and decide whether it is suitable for implanting. CBCT also ensures whether the direction of implant and the operation method are satisfactory. CBCT can be used pre- or post-operation as long as the case involves the maxillary sinus. Clinical implant cases using CBCT were introduced to evaluate the maxillary sinus pre- or post-operation.
Cone-Beam Computed Tomography ; Humans ; Maxillary Sinus ; Postoperative Period

Humans ; Hyperlipoproteinemia Type II

Objective To assess the efficacy,compliance and safety of ketogenic diet (KD) for children with infantile spasms,thus to provide an effective basis for the treatment of infantile spasms.Methods Twenty-five patients with infantile spasms were treated with KD.The gas chromatography-mass spectrometry and high performance liquid chromatography-mass spectrometry (HPLC-MS/MS) were used,except for metabolic diseases,to detect the blood routine,urine,stool,blood Iipids,liver function,as well as electrocardiogram (ECG),electroencephalograph (EEG),ultrasound of the urinary system and other related checks of all patients.The KD antiepileptic drug therapy was given after all children were admitted to hospital,and KD started directly in all patients without fasting.The efficacy compliance and safety were followed up in this study.Results KD maintenance therapy for 1 month,3 mouths,6 months were given to 25 cases (100％,25/25 cases),to 22 cases (88％,22/25 cases),and to 10 cases (40％,10/25 cases),respectively.Among them 7 patients (28％,7/25 cases) were in complete control of seizures within 1 month.Up to Class Ⅱ,Ⅲ efficacy level accounted for 32％ (8/25 cases),12％ (3/25 cases),respectively.Thirteen cases of children had varying digestive symptoms,10 cases of them developed asymptomatic hypoglycemia,and 9 cases of children had sleep trouble during KD treatment,but after symptomatic treatment,children's adverse reactions almost subsided.Only 4 cases of children discontinued treatment due to adverse reactions.All children's seizures were fully controlled.Conclusions The effect of KD is sure in the treatment of infantile spasms.Although KD has some adverse reactions,but it can be tolerated;serious body organ dysfunction treated by KD + antiepileptic drugs combination therapy for 1 to 6 months is not found yet,so the therapy is worthy of promotion clinically.

Objective To investigate and compare the therapeutic effect of aripiprazole and risperidone in the treatment of psychiatric symptoms in Alzheimer’s disease dementia. Methods 64 patients of Alzheimer's disease dementia with psychiatric symptoms,were divided into risperidone donepezil group (A) and aripiprazole donepezil group (B ) . Before and 4, 8 weeks after treatment, the BEHAV-AD scale was used to assess the pathological behavior and the side effects scale (TESS) was used to assess adverse drug reactions.Results A group at 4 weeks after treatment BEHAV-AD score showed no significant difference with before treatment ( >0.05), 8 weeks after treatment decreased significantly (<0.05) . Group B 4 weeks and 8 weeks after treatment BEHAV-AD score was significantly decreased ( <0.05) . BEHAV-AD score in Group B 4 weeks and 8 weeks after treatment was significantly lower than group A ( <0.05) .The scores in behavioral disorders, depression, anxiety in Group B were significantly lower than group A ( <0.05), the scores in paranoia ,hallucinations,aggressive behavior, delirium showed no significant difference between two groups ( >0.05) . 4 weeks after treatment,the two groups had no significant difference in TESS score ( >0.05), 8 weeks after treatment the TESS scores in group B were significantly lower in group A ( <0.05) .Conclusion Aripiprazole + donepezil can effectively alleviate the symptoms of these patients with lower mental side effects, and has better effect in treatment of Alzheimer's disease dementia with psychiatric symptoms.

It is a crucial question whether it is necessary to continue the treatment after the patients with chronic myeloid leukemia (CML) who have achieved a complete molecular response (CMR) on imatinib (IM) treatment. If tyrosine kinase inhibitor (TKI) therapy was required indefinitely to maintain CMR, the problems of financial burden and adverse effects would be increased. Approximately 40 ％ of patients with a stable CMR for at least 2 years could stop IM treatment and remain in molecular remission for at least 2 years without IM treatment. Therefore, the ultimate aim should be to give the patients long-term disease control without the need for ongoing treatment. Here the studies progresses of discontinuation of TKI therapy in CML reported in the 53th American Society of Hematology (ASH) annual meeting were reviewed.

Objective To investigate the efficacy and toxicity of thalidomide plus irinotecan and cisplatin treatment for recurrent small cell lung cancer.Methods 62 Patients with recurrent small cell lung cancer in the same period were randomly divided into observation group and control group according to the principle of minimum distribution imbalance index.The observation group patients were treated with thalidomide plus irinotecan and cisplatin chemotherapy,and the control group patients were treated with irinotecan and cisplatin chemotherapy.The efficacy and toxicity of the two groups were compared.Results The overall response rate in the group observation was 86.7％ compared with 63.3％ in the control group,and the difference had statistical significance (x2 =8.52,P ＜ 0.05).The major toxicities were hematologic toxicity and gastrointestinal symptoms,and the side effects differences were not statistically significant (x2 =0.18,P ＞ 0.05).Conclusion The treatment of recurrent small cell lung cancer with irinotecan and cisplatin in combination with thalidomide has high efficiency,and the toxicity can be tolerated.

Apolipoprotein M (apoM) is a novel apolipoprotein discovered in 1999 and belongs tothe lipocalin protein superfamily.The APOM gene is mainly expressed in the liver and kidney,Where it is highly regulated by transcription factors,cytokines,hormones etc.Series of studies have shown that apoM plays an important role in lipoprotein metabolism especially in high-density lipoprotein (HDL).Since the relationship between HDL and atherosclerosis (AS) has been well known,apoM is supposed to be of potential fuctional importance in AS.Here we review the progress made in understanding the characteristics of apoM and its relationship to cardiovascular disease.

Objective To investigate uncertainty in illness of family members of patients with malignant tumor,to explore the factors that affect uncertainty in illness of family members of patients with malignant tumor,and to provide clinical basis for clinical doctors and nurses implementing effective interventions for their patients.Methods Questionnaires were conduted to investigate uncertainty in illness of family members of patients with malignant tumor and explore the related factors.The measurements included three parts,Chinese version of Mishel uncertainty in illness scale for family member,self-designed questionnaire about family general condition,patients disease information.Results The total score of uncertainty in illness was 82.71±9.93,more than 50 ％ (75 score) of the highest PPUS-FM score.There were statistical significances of uncertainty in illness in education (F =8.06,P ＜ 0.05),family income (F=3.14,P ＜ 0.05),residence place (F =3.99,P ＜ 0.05) and frequency of hospitalization (F =4.85,P ＜ 0.05).Conclusion Family members of patients with malignant tumor have a higher level of uncertainty in illness.Education,family income,residence place and frequency of hospitalization have a certain effect on uncertainty in illness of family members of patients with malignant tumor.